The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Robert J. Motzer

Department of Medicine

Genitourinary Oncology Service

Memorial Sloan-Kettering Cancer Center

1275 York Ave.

USA

[email]@mskcc.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., USA. 2000 - 2013
  • Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address:. 2002 - 2013

References

  1. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. Motzer, R.J., Hutson, T.E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., Merchan, J.R., Boleti, E., Fife, K., Jin, J., Jones, R., Uemura, H., De Giorgi, U., Harmenberg, U., Wang, J., Sternberg, C.N., Deen, K., McCann, L., Hackshaw, M.D., Crescenzo, R., Pandite, L.N., Choueiri, T.K. N. Engl. J. Med. (2013) [Pubmed]
  2. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Motzer, R.J., Escudier, B., Tomczak, P., Hutson, T.E., Michaelson, M.D., Negrier, S., Oudard, S., Gore, M.E., Tarazi, J., Hariharan, S., Chen, C., Rosbrook, B., Kim, S., Rini, B.I. Lancet Oncol. (2013) [Pubmed]
  3. Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. Motzer, R.J., Hutson, T.E., Olsen, M.R., Hudes, G.R., Burke, J.M., Edenfield, W.J., Wilding, G., Agarwal, N., Thompson, J.A., Cella, D., Bello, A., Korytowsky, B., Yuan, J., Valota, O., Martell, B., Hariharan, S., Figlin, R.A. J. Clin. Oncol. (2012) [Pubmed]
  4. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J.A., Figlin, R.A., Hollaender, N., Kay, A., Ravaud, A. Cancer (2010) [Pubmed]
  5. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. Motzer, R.J., Hudes, G.R., Ginsberg, M.S., Baum, M.S., Harmon, C.S., Kim, S.T., Chen, I., Redman, B.G. Am. J. Clin. Oncol. (2010) [Pubmed]
  6. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G.A., Garcia-del-Muro, X., Sosman, J.A., Solska, E., Wilding, G., Thompson, J.A., Kim, S.T., Chen, I., Huang, X., Figlin, R.A. J. Clin. Oncol. (2009) [Pubmed]
  7. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Motzer, R.J., Hudes, G., Wilding, G., Schwartz, L.H., Hariharan, S., Kempin, S., Fayyad, R., Figlin, R.A. Clin. Genitourin. Cancer (2009) [Pubmed]
  8. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J.A., Figlin, R.A., Hollaender, N., Urbanowitz, G., Berg, W.J., Kay, A., Lebwohl, D., Ravaud, A. Lancet (2008) [Pubmed]
  9. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Motzer, R.J., Bukowski, R.M., Figlin, R.A., Hutson, T.E., Michaelson, M.D., Kim, S.T., Baum, C.M., Kattan, M.W. Cancer (2008) [Pubmed]
  10. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. Motzer, R.J., Hudes, G.R., Curti, B.D., McDermott, D.F., Escudier, B.J., Negrier, S., Duclos, B., Moore, L., O'Toole, T., Boni, J.P., Dutcher, J.P. J. Clin. Oncol. (2007) [Pubmed]
  11. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S.T., Chen, I., Bycott, P.W., Baum, C.M., Figlin, R.A. N. Engl. J. Med. (2007) [Pubmed]
  12. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. Motzer, R.J., Nichols, C.J., Margolin, K.A., Bacik, J., Richardson, P.G., Vogelzang, N.J., Bajorin, D.F., Lara, P.N., Einhorn, L., Mazumdar, M., Bosl, G.J. J. Clin. Oncol. (2007) [Pubmed]
  13. Targeted drugs for metastatic renal cell carcinoma. Motzer, R.J., Basch, E. Lancet (2007) [Pubmed]
  14. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Motzer, R.J., Michaelson, M.D., Redman, B.G., Hudes, G.R., Wilding, G., Figlin, R.A., Ginsberg, M.S., Kim, S.T., Baum, C.M., DePrimo, S.E., Li, J.Z., Bello, C.L., Theuer, C.P., George, D.J., Rini, B.I. J. Clin. Oncol. (2006) [Pubmed]
  15. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Motzer, R.J., Hoosen, S., Bello, C.L., Christensen, J.G. Expert. Opin. Investig. Drugs (2006) [Pubmed]
  16. Sunitinib in patients with metastatic renal cell carcinoma. Motzer, R.J., Rini, B.I., Bukowski, R.M., Curti, B.D., George, D.J., Hudes, G.R., Redman, B.G., Margolin, K.A., Merchan, J.R., Wilding, G., Ginsberg, M.S., Bacik, J., Kim, S.T., Baum, C.M., Michaelson, M.D. JAMA (2006) [Pubmed]
  17. Targeted therapy for metastatic renal cell carcinoma. Motzer, R.J., Bukowski, R.M. J. Clin. Oncol. (2006) [Pubmed]
  18. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. Motzer, R.J., Bacik, J., Schwartz, L.H., Reuter, V., Russo, P., Marion, S., Mazumdar, M. J. Clin. Oncol. (2004) [Pubmed]
  19. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. Kondagunta, G.V., Sheinfeld, J., Mazumdar, M., Mariani, T.V., Bajorin, D., Bacik, J., Bosl, G.J., Motzer, R.J. J. Clin. Oncol. (2004) [Pubmed]
  20. Predicting survival of patients with metastatic renal cell carcinoma. Motzer, R.J., Mazumdar, M. Urologe. A (2004) [Pubmed]
  21. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Motzer, R.J., Amato, R., Todd, M., Hwu, W.J., Cohen, R., Baselga, J., Muss, H., Cooper, M., Yu, R., Ginsberg, M.S., Needle, M. Invest. New. Drugs (2003) [Pubmed]
  22. Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. Motzer, R.J. Crit. Rev. Oncol. Hematol. (2003) [Pubmed]
  23. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. Motzer, R.J., Bacik, J., Murphy, B.A., Russo, P., Mazumdar, M. J. Clin. Oncol. (2002) [Pubmed]
  24. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. Motzer, R.J., Bacik, J., Mariani, T., Russo, P., Mazumdar, M., Reuter, V. J. Clin. Oncol. (2002) [Pubmed]
  25. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Motzer, R.J., Rakhit, A., Thompson, J., Gurney, H., Selby, P., Figlin, R., Negrier, S., Ernst, S., Siebels, M., Ginsberg, M., Rittweger, K., Hooftman, L. Ann. Oncol. (2002) [Pubmed]
  26. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. Motzer, R.J., Rakhit, A., Thompson, J.A., Nemunaitis, J., Murphy, B.A., Ellerhorst, J., Schwartz, L.H., Berg, W.J., Bukowski, R.M. J. Interferon Cytokine Res. (2001) [Pubmed]
  27. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. Motzer, R.J., Mazumdar, M., Sheinfeld, J., Bajorin, D.F., Macapinlac, H.A., Bains, M., Reich, L., Flombaum, C., Mariani, T., Tong, W.P., Bosl, G.J. J. Clin. Oncol. (2000) [Pubmed]
 
WikiGenes - Universities